Display options
Cite
Olsen T, Lally-Montgomery Z, Kelsberg G, et al. Is event-driven PrEP dosing for HIV as effective as daily dosing?. J Fam Pract. 2021;70(5):253-255doi: 10.12788/jfp.0207.
Olsen, T., Lally-Montgomery, Z., Kelsberg, G., Safranek, S., & Neher, J. (2021). Is event-driven PrEP dosing for HIV as effective as daily dosing?. The Journal of family practice, 70(5), 253-255. https://doi.org/10.12788/jfp.0207
Olsen, Tory, et al. "Is event-driven PrEP dosing for HIV as effective as daily dosing?." The Journal of family practice vol. 70,5 (2021): 253-255. doi: https://doi.org/10.12788/jfp.0207
Olsen T, Lally-Montgomery Z, Kelsberg G, Safranek S, Neher J. Is event-driven PrEP dosing for HIV as effective as daily dosing?. J Fam Pract. 2021 Jun;70(5):253-255. doi: 10.12788/jfp.0207. PMID: 34410919.
Copy Download .nbib Format: NLM
Share it on

J Fam Pract. 2021 Jun;70(5):253-255. doi: 10.12788/jfp.0207.

Is event-driven PrEP dosing for HIV as effective as daily dosing?.

The Journal of family practice

Tory Olsen, Zachary Lally-Montgomery, Gary Kelsberg, Sarah Safranek, Jon Neher

Affiliations

  1. Valley Family Medicine Residency, University of Washington at Valley, Renton.
  2. Health Sciences Librarian Emeritus, University of Washington Medical School, Seattle.
  3. Valley Family Medicine Residency, Renton, WA.

PMID: 34410919 DOI: 10.12788/jfp.0207

Abstract

PROBABLY, although there are no head-to-head trials comparing the 2 dosing regimens. Event-driven pre-exposure prophylaxis (PrEP) dosing reduces HIV conversion by 86% compared to placebo (strength of recommendation [SOR]: B, large randomized controlled trial [RCT]). Daily PrEP reduces HIV conversion by 44% to 86% (SOR: B, based on open-label RCTs).Event-driven PrEP regimens may be associated with lower adherence when compared with daily PrEP regimens (average of 70% for event-driven PrEP vs average of 92% for daily PrEP) (SOR: B, based on open-label and cohort trials). Event-driven PrEP regimens have lower medication costs, and they are associated with no difference in the rate of sexually transmitted infections (STIs) (SOR: B, based on prospective cohort studies). Patients may prefer them to daily regimens (75% choose event driven PrEP vs 25% choose daily PrEP) (SOR: BB, based on the preponderance of prospective cohort studies with conflicting results).

MeSH terms

Publication Types